{"id":"W2916100539","doi":"10.1016/s1470-2045(18)30907-0","title":"Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; University of Calgary","funders":"Janssen Pharmaceuticals; National Cancer Institute; Takeda Pharmaceuticals U.S.A.; Sanofi Genzyme; Genentech; National Institutes of Health; European Society for Medical Oncology; Eisai; Bayer Fund; Clovis Oncology; Active Biotech; Ipsen Biopharmaceuticals; Bavarian Nordic; Novartis; AbbVie; Exelixis; Sanofi; Merck; GlaxoSmithKline; Roche; Astellas Pharma US; Pfizer; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Retrospective cohort study; Oncology; Cohort; Internal medicine; Urology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008530888,0.0006310032,0.001095974,0.0005134301,0.0005348335,0.001278352,0.0006054317,0.0008070063,0.001940943],"category_scores_gemma":[0.002069749,0.0006871707,0.001457558,0.001561125,0.0004326387,0.0006833369,0.0005024425,0.001037245,0.0003764175],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008321092,"about_ca_system_score_gemma":0.0006557679,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008400933,"about_ca_topic_score_gemma":0.008702802,"domain_scores_codex":[0.9990621,0.0002077907,0.00009767399,0.0003491394,0.0001221648,0.0001610645],"domain_scores_gemma":[0.9984218,0.0002247134,0.0006590274,0.0003249768,0.0001526312,0.0002169082],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01334245,0.0002485906,0.9746897,0.0001966846,0.003651598,0.000689282,0.0001773237,0.0001450265,0.001983842,0.0001470748,0.0009535915,0.00377497],"study_design_scores_gemma":[0.001100148,0.001398618,0.9910591,0.00004273799,0.002424553,0.001603184,0.0003108901,0.0003480861,0.0002143789,0.0001079522,0.001353733,0.00003658162],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955081,0.002769824,0.0001411306,0.00008673762,0.00003050261,0.0000246456,0.001006337,0.000007037667,0.0004256364],"genre_scores_gemma":[0.9980714,0.0006931708,0.0001043963,0.00008118937,0.00003066421,0.00001830295,0.0007765818,0.000006354302,0.0002179348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008400933,"threshold_uncertainty_score":0.01670408,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01779356237453034,"score_gpt":0.2916839099226428,"score_spread":0.2738903475481125,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}